The prevalence of antibiotic-resistant and multidrug-resistant bacteria in urine cultures from inpatients with spinal cord injuries and disorders: an 8-year, single-center study

Vladimír Šámal1*, Vít Paldus1, Daniela Fáčková2, Jan Mečl1 and Jaroslav Šrám3

Abstract

**Background:** Patients, especially inpatients, with spinal cord lesions and disorders (SCI/D) have an elevated risk of recurrent urinary tract infections with multidrug resistant (MDR) bacteria. This study evaluated antimicrobial resistance and the prevalence of multidrug resistance and determined the risk factors for multidrug resistance.

**Methods:** In this retrospective cohort study, urine culture results were used to calculate the antimicrobial resistance rate and the incidence of infection with MDR bacteria in the SCI/D population. MDR was defined as acquired nonsusceptibility to at least one agent from three or more antimicrobial categories. The cohort included 402 inpatients from 2013 to 2020, with 1385 urine isolates. We included only the first isolate; duplicate isolates, defined as positive cultures of the same strain within 14 days, were excluded from the evaluation.

**Results:** The most common MDR strains were *Klebsiella* spp. (29%) and *Escherichia coli* (24%). MDR isolates were detected in 50% of the samples and extended spectrum beta-lactamase (ESBL)-producing isolates were detected in 26%, while carbapenem resistance was found in 0.1%. Significantly higher rates of infection with MDR bacteria were identified in groups of patients with indwelling urethral/suprapubic catheters (p = 0.003) and severity scores of C1–C4/AIS A–C (p = 0.01). We identified age (OR: 0.99, 95% CI; 0.98–0.99, p = 0.003), sex (OR: 1.55, 95% CI; 1.16–2.06, p = 0.003), management with urethral/suprapubic catheters (OR: 2.76, 95% CI; 2.04–3.74, p = 0.000), and spontaneous voiding (OR: 1.84, 95% CI; 1.03–3.29, p = 0.038) as independent predictors of multidrug resistance in our study population.

**Conclusions:** We identified a high antibiotic resistance rate and an increasing prevalence of infection with MDR bacteria in the SCI/D inpatient population. Particular attention should be given to bladder management, with an emphasis on minimizing the use of indwelling catheters.

**Keywords:** Multidrug resistance, Urinary tract infection, ESBL resistance, Spinal cord injury, Neurogenic bladder, Neurogenic lower urinary tract dysfunction

*Correspondence: vladimir.samal@nemlib.cz
1 Department of Urology, Krajská Nemocnice Liberec, Husova 10, 46063 Liberec, Czech Republic
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
complications of long-term treatment in SCI/D patients [3].

Increased bacterial resistance, especially multidrug resistance to antimicrobial agents, is now a major public health issue worldwide. Resistance to third-generation cephalosporins in *Escherichia coli* and *Klebsiella pneumoniae* is growing rapidly, primarily due to their production of extended-spectrum beta-lactamases (ESBLs), which are often associated with resistance to other antibiotics. Patients with multidrug resistant (MDR) *E. coli* and *K. pneumoniae* are often treated with carbapenems, but the number of carbapenem-resistant *Enterobacteriaceae* (CRE) isolates is increasing. In 2018, more than half of *E. coli* isolates and more than one-third of *K. pneumoniae* isolates were resistant to at least one antimicrobial group, and combined resistance was also common [4]. The increase in vancomycin-resistant isolates of *Enterococcus faecium* (VRE) is also a problem [4].

SCI/D patients repeatedly require health care and have a higher level of exposure to antibiotics, which increases the risk of infection with and colonization by MDR strains, especially by gram-negative bacteria (GNB). Infection with MDR strains is associated with a much worse outcome, prolonged length of stay, increased morbidity and mortality, and greater risk of impaired kidney function and urolithiasis, especially infectious urolithiasis [5–8]. Thus, the increase in infections with MDR bacteria is rapidly becoming a problem, especially in the inpatient setting.

In routine clinical practice, antimicrobial therapy is generally deployed upon the development of clinical signs of a UTI. To employ empirical treatments, which can be adjusted and targeted after receiving the results of antimicrobial susceptibility testing (AST), it is necessary to understand the current epidemiological context of uropathogens and the resistance rate to antimicrobial agents.

Our study was performed to assess resistance to the tested antimicrobial agents and the prevalence of infection with MDR strains in the SCI/D population with neurogenic lower urinary tract dysfunction (NLUTD) and to identify the risk factors for infection with MDR strains.

**Methods**

**Study population**

This was a retrospective cohort study focused on antimicrobial drug resistance and infection with MDR bacteria in the inpatient SCI/D population. We included patients hospitalized for SCI/D in the spinal care ward from 1 January 2013 to 31 December 2020 and obtained data from electronic medical records (EMRs) and the central database of the microbiology department. The main inclusion criterion was the development of NLUTD after SCI/D.

There were no exclusion criteria. A total of 402 adult patients were enrolled, and six patients were excluded from the evaluation (four did not have SCI/D, two had incomplete data). A total of 396 patients were evaluated (303 men and 93 women) and 1101 urine samples were collected, from which 1385 bacterial isolates were obtained. From each patient, a mean of 2.5 urine samples were collected (one sample each from 140 patients; two samples each from 103 patients; three samples each from 64 patients, and ≥ 4 urine samples each from 89 patients). At the time of their first UTI, 55% of the patients had an indwelling urethral catheter (UC), 9% had a suprapubic catheter (SC), 23% had clean intermittent catheterization (CIC), and 13% of patients were managed with spontaneous voiding (SV). The detailed characteristics are given in Table 1.

**Urine specimen collection**

In patients with spontaneous voiding, we used 5 ml of clean-catch midstream urine; in patients on the CIC regimen, urine was collected from the catheter. In patients managed with UC/SC, we used urine collected after catheter replacement. Urine collection was performed when clinical symptoms of UTI were observed, if UTI was suspected or for routine purposes.

**Urine culture**

The collected urine samples were inoculated on chromogenic agar UriSelect4® (Bio–Rad, France) within two hours. Samples taken outside working hours were stored at 2–8 °C according to preanalytical standards. An evaluation was performed after 18–24 h of aerobic incubation at 35±2 °C. Bacterial isolates were identified according to colony morphology, Gram staining, and MALDI TOF MS® mass spectrometry (Bruker, Daltonics, Germany). We considered a sample with a growth of ≥ 10^3 colony-forming units/mL of primary pathogens to be positive.

**Antimicrobial susceptibility testing**

The antibiotic disk diffusion method was used in accordance with the Guidelines and breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [9]. AST was performed on Mueller–Hinton agar (Bio–Rad, France) using antibiotic disks (Bio–Rad, France). The evaluation was performed after 16–20 h of incubation at 36 °C. The measured inhibition zones were categorized according to the EUCAST guidelines as susceptible, intermediate (changed to “susceptible—increased exposure” in 2019), or resistant [9].

Only the first bacterial isolate per patient was included in the protocol; duplicate isolates were defined as positive cultures of the same isolate obtained within 14 days of the initial isolate. Different isolates were considered different
individual isolates. Polymicrobial isolates were excluded if the individual components could not be identified.

In accordance with the European Center for Disease Prevention and Control, MDR bacteria were defined as those with acquired nonsusceptibility to at least one agent in three or more antimicrobial categories. Extensively drug-resistant (XDR) bacteria were defined as those with nonsusceptibility to at least one agent in all but two or fewer antimicrobial categories (i.e., the bacterial isolates remained susceptible to only one or two antimicrobial categories). Pandrug-resistant (PDR) bacteria were defined as those with nonsusceptibility to all agents in all antimicrobial categories [10].

*Enterobacterales* strains resistant to amoxicillin-clavulanic acid, and/or piperacillin-tazobactam and/or cefotaxime and/or meropenem were further tested using the AmpC & ESβL Detection Discs® kit (MAST, France) and it was determined whether they were ESBL-producing strains. Strains of *Enterobacterales*, *Pseudomonas aeruginosa* and *Acinetobacter* spp. resistant to meropenem in patients that were positive for carbapenemase-producing *Enterobacterales* strains (according to a β Carba Test®; Bio–Rad, France) were assessed for carbapenemase production in the National Reference Laboratory for Antibiotics (SZÚ, Prague, CZ) by MALDI TOF and PCR. *Staphylococcus aureus* strains resistant to cefoxitin and oxacillin were considered strains of methicillin-resistant *S. aureus* (MRSA). Strains of *E. faecalis* and *E. faecium* resistant to vancomycin were classified as vancomycin-resistant.

### Study endpoints

- The primary objectives of this study were to evaluate resistance (and multidrug resistance) to the tested antibiotics in this population and determine risk factors for the development of multidrug resistance.
- The secondary objectives were to evaluate the prevalence of ESBL, carbapenem, and vancomycin resistance, as well as the prevalence of methicillin-resistant *Staphylococcus aureus*, extensive drug resistance and pandrug resistance.
**Statistical methods**

We used the mean and standard deviation or the median and quartile values to describe continuous variables. To determine if the same number of patients were infected with MDR and non-MDR bacteria within each category (stratified by the variables sex, etiology, bladder management method, severity of injury, time since injury, and urinary culture), we used the Chi-square goodness-of-fit test. Univariate and multivariate logistic regression were used to determine independent predictors of multidrug resistance. The results are presented as adjusted odds ratios (ORs) with 95% confidence intervals (CIs). A significance level of 5% was used for all statistical tests. We used SPSS version 18 statistical software (IBM, IL, USA) for the statistical analysis. When the term significance is used in the text below, it means statistical significance.

**Results**

We examined the results of the urine culture and AST of 1385 bacterial isolates. Gram-negative bacteria were the most common (1191, 86.8%); the rest were gram-positive cocci. The most common strains were *Klebsiella* spp. (402, 29%), *E. coli* (329, 24%), *P. aeruginosa* (180, 13%), *E. faecalis* (174, 12%), and *P. mirabilis* (133, 10%); other strains were much less common (Table 2).

The overall prevalence of multidrug resistance in this cohort was 50% (Table 2). *P. stuarti*, *M. morganii*, and *P. vulgaris* were 100% MDR. In total, 27% of the strains were XDR, most of which were *Klebsiella* spp. (258, 64%), *P. stuarti* (21, 41%), and *P. aeruginosa* (35, 19%). Only 1% of strains were PDR. ESBL resistance was found in 26% of strains. The most common producers of ESBL were *Klebsiella* spp. (255, 63%) and *P. stuarti* (28, 55%). CPE resistance was identified in only 2 strains of *P. aeruginosa*. We did not observe MRSA or VRE strains.

The proportions of MDR strains over the study period are shown in Fig. 1. MDR strains of *P. vulgaris* became increasingly common, while the MDR strains of other species remained stable. As shown in Table 3, we found that MDR strains were significantly more common in the group of patients managed with UC/SC (*p* = 0.003). MDR strains were identified significantly less often in women (*p* = 0.006) and in patients managed with CIC (*p* = 0.000).

An overview of the rates of isolate resistance to the tested antibiotics is shown in Table 4. The results are based on AST. The resistance rates of isolates accounting for <1% of the total isolates are not listed in the table. The overall levels of resistance to aminopenicillins and amoxicillin-clavulanic acid were extremely high at 70% and 48%, respectively. The overall level of resistance to piperacillin-tazobactam was 35%. The overall level of resistance to cefuroxime was 52%, while the levels of resistance to the third- and fourth-generation cephalosporins (cefotaxime, ceftazidime and cefepime) were 43%, 22% and 20%, respectively. The overall level of resistance to ciprofloxacin was also high, at 49%. Among aminoglycosides (gentamicin and amikacin), the overall levels of resistance were 37% and 4%.

| Bacterial strain          | N (%) | MDR N (%) | XDR N (%) | PDR N (%) | ESBL N (%) | CPE N (%) | MRSA N (%) |
|---------------------------|-------|-----------|-----------|-----------|------------|-----------|------------|
| *Klebsiella* species      | 402 (29) | 346 (86) | 258 (64) | 15 (4) | 255 (63) | 0 (0) | NA         |
| *Escherichia coli*        | 329 (24) | 98 (30) | 32 (10) | 0 (0) | 43 (13) | 0 (0) | NA         |
| *Pseudomonas aeruginosa*  | 180 (13) | 48 (27) | 35 (19) | 3 (2) | 0 (0) | 2 (1) | NA         |
| *Enterococcus faecalis*   | 174 (13) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | NA         |
| *Proteus mirabilis*       | 133 (10) | 61 (46) | 3 (2) | 0 (0) | 14 (11) | 0 (0) | NA         |
| *Providencia stuartii*    | 51 (4) | 51 (100) | 21 (41) | 0 (0) | 28 (55) | 0 (0) | NA         |
| *Enterobacter species*    | 35 (3) | 30 (86) | 7 (20) | 0 (0) | 6 (17) | 0 (0) | NA         |
| *Morganella morganii*     | 27 (2) | 27 (100) | 8 (30) | 0 (0) | 2 (7) | 0 (0) | NA         |
| *Serratia marcescens*     | 19 (1) | 17 (89) | 0 (0) | 0 (0) | 3 (16) | 0 (0) | NA         |
| *Citrobacter koseri*      | 8 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | NA         |
| *Enterobacter aerogenes*  | 7 (1) | 6 (86) | 2 (29) | 0 (0) | 2 (29) | 0 (0) | NA         |
| *Proteus vulgaris*        | 6 (0) | 6 (100) | 1 (17) | 0 (0) | 1 (17) | 0 (0) | NA         |
| *Enterococcus faecium*    | 5 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | NA         |
| *Staphylococcus aureus*   | 4 (0) | 0 (0) | 2 (50) | 0 (0) | 0 (0) | 3 (75) | NA         |
| *Acinetobacter baumannii* | 3 (0) | 1 (33) | 1 (33) | 0 (0) | 0 (0) | 0 (0) | NA         |
| *Citrobacter freundii*    | 2 (0) | 1 (50) | 1 (50) | 0 (0) | 0 (0) | 0 (0) | NA         |
| Total                     | 1385 (100) | 692 (50) | 371 (27) | 18 (1) | 354 (26) | 2 (0) | 3 (0) |
respectively. We found a very low level of resistance to meropenem (4%). The level of resistance to sulfamethoxazole-trimethoprim was 63%. None of the enterococci were resistant to vancomycin.

Overall, the lowest levels of resistance (<10%) were to meropenem and amikacin.

We identified specific risk factors associated with the isolation of MDR strains. Based on the univariate analysis, we identified four variables associated with the development of MDR strains, namely, age, sex, bladder management method and severity of the injury (Table 5).

We used the enter method of multivariate logistic regression (Table 6) to identify the variables that were independently associated with the development of MDR strains. Increased age (OR: 0.99, 95% CI; 0.98–0.99, p = 0.000), male sex (OR: 1.55, 95% CI; 1.16–2.06, p = 0.003), UC/SC bladder management (OR: 2.76, 95% CI; 2.0–3.74, p = 0.000), and SV bladder management (OR: 1.84, 95% CI: 1.03–3.29, p = 0.038) were found to be independent predictors of the development of MDR strains in our study population.

**Discussion**

Our work provides an overview of urine culture results and AST in spinal ward patients over a period of eight years. We evaluated all positive urinary findings to obtain an overview of the rates of antibiotic resistance, enzymatically conditioned resistance, and multidrug resistance. Knowledge of these parameters is important for selecting a specific antimicrobial therapy before the final results of AST are obtained. Many infected SCI/D patients are in critical condition, and knowledge of the epidemiological data and estimated resistance rates in these patients can affect the success of empirical antibiotic therapy. Infection with MDR strains increases patients’ morbidity and mortality, increases the likelihood of rehospitalization, prolongs the length of stay, and has a significant effect on the cost of treatment [11].

Because the primary objective of this study was to determine the prevalence of uropathogens and the rates of resistance, including multidrug resistance, we did not consider whether these infections were symptomatic UTIs or asymptomatic bacteriuria. Indeed, a detailed assessment of this aspect would be error-prone given the retrospective nature of our study, which was based on data from EMRs.

We used the current definition of multidrug resistance, which was adopted based on the consensus reached by an international expert panel in 2011 [10]. These guidelines established epidemiologically significant categories of antibiotics for each group of bacteria and defined MDR bacteria as those with nonsusceptibility to at least one agent in ≥3 antimicrobial categories. Most of the studies conducted before this consensus used a different
definition of MDR bacteria, which was usually less strict. Therefore, it is difficult to compare our results with those of studies published before 2011.

In our study, which exclusively involved inpatients, 50% of the isolates were MDR bacteria, and the proportion of XDR bacteria was relatively high (27%). Fitzpatrick et al. found that 36.1% of GNB isolated from urine were MDR strains, one-fifth of which were obtained from outpatients [12]. The most common uropathogens were *E. coli* (27%), *K. pneumoniae* (16%) and *P. aeruginosa* (17.3%). They observed a significant shift among the resistant pathogens from gram-positive cocci to GNB over 9 year of follow-ups. Significant geographical differences in MDR bacteria were also observed. The results of other studies on the SCI/D population have shown a prevalence of MDR at rates of 60.7%, 41.3%, or 33% [11, 13, 14]. In general, an increase in the prevalence of resistant strains in recent years has been reported in several other studies [12, 15, 16]. Large regional differences in the occurrence and proportion of MDR strains have also been reported [11, 14].

In our cohort, the most common strains were *Klebsiella* spp. (29%), *E. coli* (24%) and *P. aeruginosa* (13%). Most similar studies have reported that *E. coli* is the dominant uropathogen in SCI/D patients, with a significantly lower proportion of *Klebsiella* spp. [12, 14, 17]. The relatively high proportion of patients managed with UC/SC, due to the acute nature of the spinal ward, is a possible reason for the high incidence of infection with *Klebsiella* spp. in our group. Most patients in this ward are hospitalized for an average of three months after injury before being transferred to a special rehabilitation institution for patients with SCI/D. In the present cohort, 15% of patients with polytrauma were receiving long-term management with UC/SC. This may partially explain the high prevalence of MDR strains and the identification of nosocomial strains of *Klebsiella* spp. The frequent use of broad-spectrum antibiotics for indications other than UTIs, which leads to the selection of MDR strains, may also explain these findings.

We observed an increase in ESBL production in *Enterobacterales* (26%). Prior administration of fluoroquinolones and third- and fourth-generation cephalosporins appears to be a risk factor for ESBL production [18]. The increasing trend in ESBL production is supported by another study that identified ESBL production in 6.6% of *E. coli* and *K. pneumoniae* strains [19]. We did not observe carbapenem resistance in our cohort; the estimated rate of CRE in SCI/D patients in other studies was 1.7–7.6% [13, 20]. Compared with other studies, this study reported a lower prevalence of MRSA [6, 21]. Thus, there is a clear trend in recent years, with a shift among MDR bacteria from gram-positive cocci to GNB [6].

Based on our overview of bacterial strains and the rates of resistance to various antibiotics, there is clear evidence of a high proportion of nosocomial strains, mostly GNB. Bacterial colonization occurs through the spread of strains derived from the intestinal microflora, perineum, or urethra when the catheter is manipulated [22]. Contamination from the patient’s external environment and transmission between patients and by medical staff are also common. Colonization can persist in the long term without any signs of an acute UTI. However, if colonization occurs, the patient is at risk for lifelong recurrent UTIs. The prevalence of multidrug resistance and other types of resistance in the general population varies between hospitals, wards and specific patient populations. The prevalence of resistance is influenced by the specific patient population, antibiotic policies and established clinical practices.

Bacterial antimicrobial resistance is usually genetically encoded. In addition to the traditional method of antimicrobial susceptibility testing, sequencing-based methods expand our ability to assess antimicrobial resistance.

### Table 3 Prevalences of MDR and non-MDR strains in groups of patients

| Sex           | MDR N (%) | Non MDR N (%) | p-value |
|---------------|-----------|---------------|---------|
| Male          | 579 (52)  | 535 (48)      | 0.187   |
| Female        | 113 (42)  | 158 (58)      | **0.006** |
| Etiology      |           |               |         |
| Non-traumatic | 104 (47)  | 118 (53)      | 0.347   |
| Traumatic     | 588 (51)  | 575 (49)      | 0.703   |
| Bladder management |       |               |         |
| UC or SC      | 559 (55)  | 464 (45)      | **0.003** |
| CIC           | 105 (36)  | 186 (64)      | **0.000** |
| SV            | 28 (39)   | 43 (61)       | 0.075   |
| Severity of injury |       |               |         |
| C1–C4, AIS A or B or C | 133 (59) | 94 (41)       | **0.010** |
| CS–C8, AIS A or B or C | 120 (47) | 134 (53)      | 0.380   |
| T1–S5, AIS A or B or C | 293 (50) | 290 (50)      | 0.901   |
| AIS D         | 145 (46)  | 171 (54)      | 0.144   |
| Time since injury |       |               |         |
| < 1 year      | 467 (49.0) | 486 (51.0)   | 0.538   |
| 1–5 years     | 78 (56.5) | 60 (43.5)     | 0.125   |
| 6–10 years    | 37 (50.0) | 37 (50.0)     | 1.000   |
| > 10 years    | 110 (50.0) | 110 (50.0)    | 1.000   |
| Urinary culture |       |               |         |
| Gram-negative | 692 (58)  | 510 (42)      | **0.000** |
| Gram-positive | 0 (0)     | 183 (100)     | **0.000** |

Bold value means significant values.

AIS The American Spinal Injury Association Impairment scale, UC indwelling urethral catheter, SC suprapubic catheter, CIC clean intermittent catheterization, SV spontaneous voiding.
### Table 4: Antibiotic resistance rates of main isolates from urine culture

| Antibiotics          | Klebsiella species | Escherichia coli | Proteus mirabilis | Providencia stuartii | Enterobacter species | Morganella morganii | Serratia marcescens |
|----------------------|--------------------|------------------|-------------------|----------------------|----------------------|---------------------|---------------------|
| Amikacin             | 13 (3) 398         | 3 (1) 329        | 1 (1) 132         | 1 (2) 51             | 1 (3) 35             | 0 (0) 26            | 0 (0) 19            |
| Aminopenicillin      | 402 (100) 402      | 200 (61) 329     | 81 (61) 132       | 51 (100) 51          | 35 (100) 35          | 27 (100) 27         | 19 (100) 19         |
| Amoxicillin-CAp       | 292 (73) 402       | 53 (16) 329      | 7 (5) 133         | 51 (100) 51          | 34 (97) 35           | 24 (89) 27          | 19 (100) 19         |
| Cefepim              | –                  | –                | –                 | –                    | –                    | –                   | –                   |
| Cefotaxim            | 304 (76) 402       | 53 (16) 329      | 15 (11) 132       | 27 (53) 51           | 14 (40) 35           | 11 (41) 27          | 7 (37) 19           |
| Cefazolin            | –                  | –                | –                 | –                    | –                    | –                   | –                   |
| Cefuroxim            | 310 (78) 395       | 57 (18) 315      | 18 (15) 121       | 41 (85) 48           | 30 (100) 30          | 23 (88) 26          | 17 (100) 17         |
| Ciprofloxacin        | 288 (72) 401       | 96 (29) 329      | 63 (47) 133       | 47 (92) 51           | 6 (17) 35            | 12 (44) 27          | 1 (5) 19            |
| Colistin             | –                  | –                | –                 | –                    | –                    | –                   | –                   |
| Gentamicin           | 259 (64) 402       | 39 (12) 329      | 52 (39) 132       | 24 (47) 51           | 6 (17) 35            | 11 (42) 26          | 0 (0) 19            |
| Gentamicin2          | –                  | –                | –                 | –                    | –                    | –                   | –                   |
| Chloramphenicol      | –                  | –                | –                 | 1 (100) 1            | –                    | –                   | 0 (0) 1             |
| SMX-TMPd             | 337 (84) 401       | 145 (44) 328     | 88 (66) 133       | 37 (73) 51           | 6 (17) 35            | 14 (52) 27          | 1 (5) 19            |
| Linezolid            | –                  | –                | –                 | –                    | –                    | –                   | –                   |
| Meropenem            | 1 (0) 372          | 0 (0) 290        | 0 (0) 120         | 0 (0) 42             | 0 (0) 33             | 0 (0) 25            | 0 (0) 17            |
| Nitrofurantoin       | –                  | –                | –                 | –                    | –                    | –                   | –                   |
| Piperacillin–tazobactam | 277 (70) 395     | 40 (12) 327      | 1 (1) 132         | 10 (20) 51           | 14 (41) 34           | 10 (37) 27          | 6 (32) 19           |
| Tigecycline          | –                  | –                | –                 | –                    | –                    | –                   | –                   |
| Vankomycin           | –                  | –                | –                 | –                    | –                    | –                   | –                   |
Table 4 (continued)

| Bacterial strain | Pseudomonas aeruginosa | Enterococcus faecalis | Total of Agens |
|------------------|------------------------|-----------------------|---------------|
| Antibiotics      | Resistant N (%) | Total N | Resistant N (%) | Total N | Resistant N (%) | Total N |
| Amikacin         | 23 (18) | 131 | – | – | 42 (4) | 1121 |
| Aminopenicillin  | – | – | 1 (1) | 174 | 816 (70) | 1169 |
| Amoxicillin-CA<sup>b</sup> | – | – | – | – | 480 (48) | 996 |
| Cefepim          | 36 (20) | 180 | – | – | 36 (20) | 180 |
| Cefotaxim        | – | – | – | – | 431 (43) | 995 |
| Ceftazidim       | 39 (22) | 180 | – | – | 39 (22) | 180 |
| Cefuroxim        | – | – | – | – | 496 (52) | 952 |
| Ciprofloxacin    | 65 (36) | 179 | – | – | 578 (49) | 1174 |
| Colistin         | 0 (0) | 20 | – | – | 0 (0) | 20 |
| Gentamicin       | 44 (25) | 179 | – | – | 435 (37) | 1173 |
| Gentamicin<sup>c</sup> | – | – | 74 (43) | 173 | 74 (43) | 173 |
| Chloramphenicol  | – | – | – | – | 1 (50) | 2 |
| SMX-TMP<sup>d</sup> | – | – | – | – | 628 (63) | 994 |
| Linezolid        | – | – | 0 (0) | 60 | 0 (0) | 60 |
| Meropenem        | 41 (23) | 179 | – | – | 42 (4) | 1078 |
| Nitrofurantoin   | – | – | 0 (0) | 174 | 0 (0) | 174 |
| Piperacillin–tazobactam | 51 (28) | 180 | – | – | 409 (35) | 1165 |
| Tigecyclin       | – | – | 0 (0) | 174 | 0 (0) | 174 |
| Vankomycin       | – | – | 0 (0) | 172 | 0 (0) | 172 |

<sup>a</sup> Enterobacterales  
<sup>b</sup> CA clavulanic acid  
<sup>c</sup> Gentamycin for synergy  
<sup>d</sup> SMX-TMP- sulfomethoxazol-trimetoprim
Whole-genome sequencing to detect genetic determinants of antimicrobial resistance is available and provides rapid and sensitive determination of resistance [23]. In our work, UC/SC bladder management, male sex, and injury severity were identified as risk factors for multidrug resistance. Other studies have reported similar findings [19, 24–26]. The most common risk factor for MDR was management with UC/SC. Other risk factors include a history of UTIs, previous antimicrobial therapy, and prolonged and repeated exposure to antimicrobials [27]. One of the basic methods for preventing multidrug resistance should be the early removal of indwelling catheters, as the prophylactic effect of management with CIC has been shown [28–31]. Another risk factor for MDR was spontaneous voiding. We consider this to indicate long-term colonization that persisted after switching from UC/SC to spontaneous voiding management methods. Risk factors for acquired resistance in different species have also been identified, but a detailed assessment of these factors is beyond the scope of this study.

We found a high level of resistance to antibiotics, especially aminopenicillins, amoxicillin-clavulanic acid, cephalosporins, fluoroquinolones and SMX-TMP, which are commonly used to treat UTIs. Other studies have found similar results [12, 26, 32].

Our work is limited by a number of factors. First, it was a retrospective study with data collected from one center. Although the sample size was relatively large, the findings need to be validated in a multicenter study. Second, clinically symptomatic infections and asymptomatic bacteriuria were not considered separately. The colonization of the lower urinary tract by MDR bacteria in patients with neurogenic bladder is generally high. Thus, the difference between symptomatic UTI and asymptomatic bacteriuria merits further investigation. Future studies are needed. Third, the results of this study could have been affected by regional trends, established clinical practices, and local antibiotic policies.

**Conclusion**

In this large cohort of SCI/D inpatients with neurogenic lower urinary tract dysfunction, we observed increasing resistance among uropathogens and a high prevalence of MDR strains. In particular, the use of an indwelling catheter is a risk factor for infection with MDR bacteria.

**Table 5** Univariate analysis of the risk of multidrug resistance

| Variable                              | MDR N (%) | Non MDR N (%) | Adjust OR | 95% CI       | p-value |
|---------------------------------------|-----------|---------------|-----------|--------------|---------|
| Age (mean ± SD)                       | 48 ± 17   | 51 ± 18       | 0.99      | 0.98–0.99    | 0.002   |
| Sex                                   |           |               |           |              |         |
| Male                                  | 579 (52)  | 535 (48)      | 1.51      | 1.16–1.98    | 0.003   |
| Female                                | 113 (42)  | 158 (58)      | Reference |              |         |
| Etiology                              |           |               |           |              |         |
| Non-traumatic                         | 104 (47)  | 118 (53)      | Reference |              |         |
| Traumatic                             | 588 (51)  | 575 (49)      | 1.16      | 0.87–1.55    | 0.311   |
| Bladder management                    |           |               |           |              |         |
| CIC                                   | 105 (36)  | 186 (64)      | Reference |              |         |
| UC/SC                                 | 559 (55)  | 464 (45)      | 2.13      | 1.63–2.79    | 0.000   |
| SV                                    | 28 (39)   | 43 (61)       | 1.15      | 0.68–1.97    | 0.599   |
| Severity of injury                    |           |               |           |              |         |
| AIS D                                 | 145 (46)  | 171 (54)      | Reference |              |         |
| C1–C4, AIS A or B or C               | 133 (59)  | 94 (41)       | 1.67      | 1.18–2.36    | 0.004   |
| CS–C8, AIS A or B or C               | 120 (47)  | 134 (53)      | 1.06      | 0.76–1.47    | 0.747   |
| T1–S5, AIS A or B or C               | 293 (50)  | 290 (50)      | 1.19      | 0.91–1.57    | 0.211   |
| Time since injury                     |           |               |           |              |         |
| 5 years                               | 467 (49.0)| 486 (51.0)    | Reference |              |         |
| 1–5 years                             | 78 (56.5) | 60 (43.5)     | 1.35      | 0.94–1.94    | 0.100   |
| 6–10 years                            | 37 (50.0) | 37 (50.0)     | 1.04      | 0.65–1.67    | 0.869   |
| > 10 years                            | 110 (50.0)| 110 (50.0)    | 1.04      | 0.78–1.40    | 0.790   |

Bold value means significant values

AIS The American Spinal Injury Association Impairment scale, UC indwelling urethral catheter, SC suprapubic catheter, CIC clean intermittent catheterization, SV spontaneous voiding
Table 6  Multivariate analysis

| Variable                      | Adjust OR | 95% CI     | p-value |
|-------------------------------|-----------|------------|---------|
| Age                           | 0.99      | 0.98–0.99  | 0.000   |
| Sex                           |           |            |         |
| Male                          | 1.55      | 1.16–2.06  | 0.003   |
| Female                        | Reference |            |         |
| Etiology                      |           |            |         |
| Non-traumatic                 | 1.09      | 0.78–1.53  | 0.615   |
| Traumatic                     | Reference |            |         |
| Bladder management            |           |            |         |
| CIC                           | Reference |            |         |
| UC or SC                      | 2.76      | 2.04–3.74  | 0.000   |
| SV                            | 1.84      | 1.03–3.29  | 0.038   |
| Severity of injury            |           |            |         |
| AIS D                         | Reference |            |         |
| C1–C4, AIS A or B or C        | 0.95      | 0.64–1.40  | 0.795   |
| C5–C8, AIS A or B or C        | 0.71      | 0.50–1.02  | 0.067   |
| T1–T55, AIS A or B or C       | 0.98      | 0.73–1.32  | 0.903   |
| Time since injury             |           |            |         |
| <1 year                       | Reference |            |         |
| 1–5 years                     | 1.29      | 0.88–1.88  | 0.188   |
| 6–10 years                    | 1.23      | 0.74–2.03  | 0.423   |
| >10 years                     | 1.26      | 0.92–1.73  | 0.157   |
| Constant                      | 1.23      | 0.55–2.82  | 0.558   |

Bold value means significant values

AIS The American Spinal Injury Association Impairment scale, UC indwelling urethral catheter, SC suprapubic catheter, CIC clean intermittent catheterization, SV spontaneous voiding

Abbreviations
AST: Antimicrobial susceptibility testing; CFU: Colony forming unit; CIC: Clean intermittent catheterization, CRE: Carbapenem resistance; ESBL: Extended-spectrum beta-lactamases; GNB: Gram-negative bacteria; MDR: Multidrug resistant; PDR: Pandrug resistant; SCI/D: Spinal cord injury and disorders; VRE: Vancomycin resistant; UTI: Urinary tract infection; XDR: Extensively drug resistant.

Acknowledgements
The authors would like to thank Hana Kolářová, Ph.D. for assistance with data processing and statistical evaluation.

Authors’ contributions
Study concept and design: VS and VP. Data analysis and interpretation: VS. Microbiology expertise: DF. Manuscript preparation: VS and VP. Manuscript review: VS, JM, and JŠ. All authors read and approved the final manuscript.

Funding
This work was supported by funding from the Scientific Board of Krajská nemocnice Liberec, a.s.

Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available because the local ethics committee require oversight of use of research data but are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study was conducted in accordance with Good Clinical Practices and the principles of the Declaration of Helsinki. The study was approved by the relevant Institutional Review Board of Krajská nemocnice Liberec a.s. Written informed consent was obtained from all study participants.

Consent for publication
Not applicable.

Competing interests
The authors declare no conflicts of interest.

Author details
1 Department of Urology, Krajská Nemocnice Liberec, Husova 10, 46063 Liberec, Czech Republic. 2 Department of Microbiology, Krajská Nemocnice Liberec, Liberec, Czech Republic. 3 Traumatology and Orthopedics Center, Krajská Nemocnice Liberec, Liberec, Czech Republic.

Received: 3 November 2021 Accepted: 2 March 2022

Published online: 09 March 2022

References
1. Penders J, Huylenbroeck AA, Everaert K, Van Laere M, Verschraegen GL. Urinary infections in patients with spinal cord injury. Spinal Cord. 2003;41:549–52.
2. Esclainn De Ruz A, Garcia Leoni E, Herruzo Cabrera R. Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury. J Urol. 2000;164:1285–9.
3. Adriaansen JJ, Ruizs LE, van Koppenhagen CF, van Asbeck FW, Snoek GJ, van Kuppevelt D, et al. Secondary health conditions and quality of life in persons living with spinal cord injury for at least ten years. J Rehabil Med. 2016;48:853–60.
4. Control ECIDPa. Surveillance of antimicrobial resistance in Europe 2018 [Internet]. 2020. Available from: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2018.
5. Rabadi MH, Aston CE. Predictors of mortality in veterans with multiple sclerosis in an outpatient clinic setting. Int J MS Care. 2017;19:265–73.
6. Waits KB, Canupp KC, Chen Y, DeVivo MJ, Moser SA. Bacteremia after spinal cord injury in initial versus subsequent hospitalizations. J Spinal Cord Med. 2001;24:96–100.
7. Hsiao CY, Yang HY, Chang CH, Lin HL, Wu CY, Hsiao MC, et al. Risk factors for development of septic shock in patients with urinary tract infection. Biomed Res Int. 2015;2015:717094.
8. Welk B, Fuller A, Razvi H, Denstedt J. Renal stone disease in spinal-cord-injured patients. J Endourol. 2012;26:954–9.
9. (EU-CAST) ECoASt. Clinical breakpoints - breakpoints and guidance [Internet]. 2020. Available from: https://www.eucast.org/ast_of_bacteria/
10. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.
11. Ramanathan S, Fitzpatrick MA, Suda KJ, Burns SP, Jones MM, LaVela SL, et al. Multidrug-resistant gram-negative organisms and association with 1-year mortality, readmission, and length of stay in Veterans with spinal cord injuries and disorders. Spinal Cord. 2020;58:596–608.
12. Fitzpatrick MA, Suda KJ, Saldaf N, Burns SP, Jones MM, Poggesse L, et al. Changes in bacterial epidemiology and antibiotic resistance among veterans with spinal cord injury/disorder over the past 9 years. J Spinal Cord Med. 2018;41:199–207.
13. Suda KJ, Patel UC, Sabzwari R, Cao L, Ramanathan S, Hill JN, et al. Bacterial susceptibility patterns in patients with spinal cord injury and disorder (SCI/D): an opportunity for customized stewardship tools. Spinal Cord. 2016;54:1001–9.
14. Evans CT, Fitzpatrick MA, Jones MM, Burns SP, Poggensee L, Ramanathan S, et al. Prevalence and factors associated with multidrug-resistant gram-negative organisms in patients with spinal cord injury. Infect Control Hosp Epidemiol. 2017;38:1464–71.

15. Forster CS, Courter J, Jackson EC, Mortensen JE, Haslam DB. Frequency of multidrug-resistant organisms cultured from urine of children undergoing clean intermittent catheterization. J Pediatric Infect Dis Soc. 2017;6:332–8.

16. Fan NC, Chen HH, Chen CL, Ou LS, Lin TY, Tsai MH, et al. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children. J Microbiol Immunol Infect. 2014;47:399–405.

17. Mortazavi-Tabatabaei SAR, Ghaderkhani J, Nazari A, Sayehmiri K, Sayehmiri F, Pakzad I. Pattern of antibacterial resistance in urinary tract infections: a systematic review and meta-analysis. Int J Prev Med. 2019;10:169.

18. Fitzpatrick MA, Suda KJ, Saefdar N, Goldstein B, Jones MM, Poggensee L, et al. Unique risks and clinical outcomes associated with extended-spectrum β-lactamase enterobacteriaceae in veterans with spinal cord injury or disorder: a case–case–control study. Infect Control Hosp Epidemiol. 2016;37:768–76.

19. Toner L, Papa N, Aliyu SH, Dev H, Lawrentschuk N, Al-Hayek S. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. World J Urol. 2016;34:1031–7.

20. Fitzpatrick MA, Suda KJ, Jones MM, Burns SP, Poggensee L, Ramanathan S, et al. Effect of varying federal definitions on prevalence and characteristics associated with carbapenem-resistant Enterobacteriaceae in veterans with spinal cord injury. Am J Infect Control. 2019;47:175–9.

21. Girard R, Mazoyer MA, Plauchu MM, Rode G. High prevalence of nosocomial infections in rehabilitation units accounted for by urinary tract infections in patients with spinal cord injury. J Hosp Infect. 2006;62:473–9.

22. Waites KB, Canupp KC, DeVivo MJ. Microbiology of the urethra and periurethral bacteria in community-residing men with spinal cord injury. J Spinal Cord Med. 2004;27:448–52.

23. Boolchandani M, D’Souza AW, Dantas G. Sequencing-based methods and resources to study antimicrobial resistance. Nat Rev Genet. 2019;20:336–70.

24. Ryu KH, Kim YB, Yang SO, Lee JK, Jung TY. Results of urine culture and antimicrobial sensitivity tests according to the voiding method over 10 years in patients with spinal cord injury. Korean J Urol. 2011;52:345–9.

25. Kang MS, Lee BS, Lee HJ, Hwang SW, Han ZA. Prevalence of and risk factors for multidrug-resistant bacteria in urine cultures of spinal cord injury patients. Ann Rehabil Med. 2015;39:686–95.

26. Waites KB, Chen Y, DeVivo MJ, Canupp KC, Moser SA. Antimicrobial resistance in gram-negative bacteria isolated from the urinary tract in community-residing persons with spinal cord injury. Arch Phys Med Rehabil. 2000;81:764–9.

27. Cardenas DD, Hooton TM. Urinary tract infection in persons with spinal cord injury. Arch Phys Med Rehabil. 1995;76:272–80.

28. Wyndaele JJ, Brauner A, Geerlings SE, Bela K, Peter T, Bjerklund-Johanson TE. Clean intermittent catheterization and urinary tract infection: review and guide for future research. BJU Int. 2012;110:E910–7.

29. Cardenas DD, Moore KN, Dannels-McClure A, Scelza WM, Graves DE, Brooks M, et al. Intermittent catheterization with a hydrophilic-coated catheter delays urinary tract infections in acute spinal cord injury—a prospective, randomized, multicenter trial. Pm R. 2013;13:408–17.

30. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:625–63.

31. Truzzi JC, de Almeida FG, Sacomani CA, Reis J, Rocha FET. Neurogenic bladder—concepts and treatment recommendations. Int Braz J Urol. 2021;47.

32. Yoon SB, Lee BS, Lee KD, Hwang SI, Lee HJ, Han ZA. Comparison of bacterial strains and antibiotic susceptibilities in urinary isolates of spinal cord injury patients from the community and hospital. Spinal Cord. 2014;52:298–301.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.